Healthcare · Biotechnology
Price
$2.27
Market Cap
$313.9M
Employees
35
Beta
0.74
Avg Volume
8,051,009
CEO
Thomas J. Schuetz
Business Description
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Business History
Price Overview
Price at report time · Jul 3, 4:50am (0m ago)
$2.27
Change · Jul 3
+0.09 (+4.13%)
Day Range
$2.17 – $2.28
52-Week Range
$1.61 – $6.88
50-Day MA
$2.20
200-Day MA
$4.37
Volume
2,695,059.00
Right now · live
loading…
Real-time — the change above is the move since the report (over 0m).
Analyst Price Targets
Low
$6.00
Consensus
$10.40
High
$15.00
(9 analysts)
Share Structure
Outstanding
138,286,301.00
Float
97,028,680.00
Free Float
70.2%
Normal free float
— 70.2% of shares trade freely, ~29.8% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-5.40
Stock Price: $2.27
EPS (Diluted): -0.42
EPS (Diluted): -0.42
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.30
Stock Price: $2.27
Total Equity: $196.79M
Shares: 157,695,000
Total Equity: $196.79M
Shares: 157,695,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-4.01
Market Cap: $313.91M
Total Debt: $8.83M
Cash: $30.64M
EBITDA: -$65.02M
Total Debt: $8.83M
Cash: $30.64M
EBITDA: -$65.02M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$826.0M
Market Cap: $313.91M
Total Debt: $8.83M
Cash: $30.64M
Total Debt: $8.83M
Cash: $30.64M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $2.27
Revenue: $0.00
Shares: 157,695,000
Revenue: $0.00
Shares: 157,695,000
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$1.47M
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$72.84M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$66.49M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-39.7%
Net Income: -$66.49M
Total Equity: $196.79M
Total Equity: $196.79M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-38.3%
Operating Income: -$72.84M
Tax Rate: 0.0%
Equity: $196.79M
Total Debt: $8.83M
Cash: $30.64M
Tax Rate: 0.0%
Equity: $196.79M
Total Debt: $8.83M
Cash: $30.64M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
15.02
Current Assets: $209.82M
Current Liabilities: $13.97M
Current Liabilities: $13.97M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.04
Short-Term Debt: $0.00
Long-Term Debt: $8.83M
Total Debt: $8.83M
Total Equity: $196.79M
Long-Term Debt: $8.83M
Total Debt: $8.83M
Total Equity: $196.79M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 157,695,000
Shares: 157,695,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.25
Total Equity: $196.79M
Shares: 157,695,000
Shares: 157,695,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.31
Operating CF: -$49.14M
CapEx: -$25,000
Shares: 157,695,000
CapEx: -$25,000
Shares: 157,695,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.27
Stock Price: $2.27
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$66.49M
Net Income: -$66.49M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CMPX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $850,000 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $1.5M |
| Gross Profit | $0 | $0 | $0 | $850,000 | -$1.5M |
| Operating Expenses | $81.9M | $41.7M | $50.4M | $57.5M | $71.4M |
| Operating Income | -$81.9M | -$41.7M | -$50.4M | -$56.6M | -$72.8M |
| Net Income | -$82.2M | -$39.2M | -$42.5M | -$49.4M | -$66.5M |
| EBITDA | -$80.2M | -$35.0M | -$40.6M | -$47.6M | -$65.0M |
| EPS | $-1.31 | $-0.35 | $-0.33 | $-0.36 | $-0.42 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $144.5M | $34.9M | $24.2M | $43.5M | $30.6M |
| Total Current Assets | $147.1M | $194.8M | $153.9M | $132.8M | $209.8M |
| Total Assets | $153.8M | $199.6M | $156.9M | $140.4M | $219.6M |
| Current Liabilities | $10.6M | $16.2M | $7.8M | $8.9M | $14.0M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $8.8M |
| Total Liabilities | $13.7M | $18.0M | $8.3M | $15.2M | $22.8M |
| Total Equity | $140.1M | $181.6M | $148.5M | $125.2M | $196.8M |
| Retained Earnings | -$233.6M | -$272.8M | -$315.3M | -$364.7M | -$431.2M |
Cash Flow (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$19.7M | -$34.1M | -$40.6M | -$44.9M | -$49.1M |
| Capital Expenditure | -$1.6M | $-212,000 | $-30,000 | $-44,000 | $-25,000 |
| Free Cash Flow | -$21.2M | -$34.3M | -$40.6M | -$44.9M | -$49.2M |
| Acquisitions (net) | $116,000 | $176,000 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $-159 | $0 | $0 |
| Net Change in Cash | $97.2M | -$109.6M | -$10.7M | $19.3M | -$12.8M |
Analyst Estimates (Annual)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$25.9M $2.7M – $67.1M
|
$126.9M $126.9M – $126.9M
|
$264.3M $105.9M – $524.2M
|
$378.0M $151.5M – $749.7M
|
| EBITDA |
$15.5M $1.6M – $40.3M
|
$76.1M $76.1M – $76.1M
|
$158.6M $63.5M – $314.5M
|
$226.8M $90.9M – $449.8M
|
| Net Income |
-$89.8M -$108.1M – -$35.0M
|
-$28.0M -$105.7M – $50.5M
|
$47.2M $10.4M – $107.5M
|
$103.6M $22.9M – $236.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 3, 2026 4:50am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | -100.0% |
| Gross Profit Growth | — | — | — | -273.2% |
| Operating Income Growth | +49.1% | -20.9% | -12.4% | -28.6% |
| Net Income Growth | +52.3% | -8.3% | -16.2% | -34.7% |
| EBITDA Growth | +56.4% | -16.1% | -17.3% | -36.5% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-29 | Lerner Neil | P-Purchase | 15,000.00 | $1.89 | $28,350 |
| 2026-04-29 | Anderman Jonathan | P-Purchase | 25,000.00 | $1.89 | $47,250 |
| 2026-04-29 | Anderman Jonathan | A-Award | 25,000.00 | $1.89 | $47,250 |
| 2026-04-29 | Lerner Neil | A-Award | 15,000.00 | $1.89 | $28,350 |
| 2026-02-08 | Schuetz Thomas J. | F-InKind | 36,687.00 | $6.52 | $239,199 |
| 2026-01-09 | Schuetz Thomas J. | F-InKind | 46,777.00 | $5.35 | $250,257 |
| 2026-01-02 | Shin Barry | A-Award | 670,000.00 | $5.17 | $3.5M |
| 2026-01-02 | Shin Barry | A-Award | 125,000.00 | $5.17 | $646,250 |
| 2026-01-02 | Sirard Cynthia | A-Award | 1,000,000.00 | $5.17 | $5.2M |
| 2026-01-02 | Schuetz Thomas J. | A-Award | 250,000.00 | $5.17 | $1.3M |
| 2026-01-02 | Schuetz Thomas J. | A-Award | 2,000,000.00 | $5.17 | $10.3M |
| 2026-01-02 | Prasad Arjun | A-Award | 1,000,000.00 | $5.17 | $5.2M |
| 2026-01-02 | LINDAHL RICHARD S | A-Award | 90,000.00 | $5.17 | $465,300 |
| 2026-01-02 | Chiniara Ellen | A-Award | 90,000.00 | $5.17 | $465,300 |
| 2026-01-02 | Lerner Neil | A-Award | 435,000.00 | $5.17 | $2.2M |
| 2026-01-02 | Lerner Neil | A-Award | 62,500.00 | $5.17 | $323,125 |
| 2026-01-02 | GRAY MARY ANN | A-Award | 90,000.00 | $5.17 | $465,300 |
| 2026-01-02 | Boylan James P | A-Award | 90,000.00 | $5.17 | $465,300 |
| 2026-01-02 | GORDON CARL L | A-Award | 90,000.00 | $5.17 | $465,300 |
| 2026-01-02 | Ferneau Philip | A-Award | 90,000.00 | $5.17 | $465,300 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CMPX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CMPX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.373 · 697c9e64 · 2026-07-02 20:17:59